Technical Analysis for TRVI - Trevi Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -7.67% | |
| Crossed Above 200 DMA | Bullish | -7.67% | |
| Pocket Pivot | Bullish Swing Setup | -7.67% | |
| NR7 | Range Contraction | -1.77% | |
| Narrow Range Bar | Range Contraction | -1.77% | |
| Lower Bollinger Band Walk | Weakness | -1.77% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 20 hours ago |
| Down 5% | about 20 hours ago |
| Down 3% | about 20 hours ago |
| Fell Below 200 DMA | about 20 hours ago |
| Down 2 % | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/06/2024
Trevi Therapeutics, Inc. Description
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Organic Compounds Chemical Compounds Opioids Analgesics Idiopathic Pulmonary Fibrosis Ethers Pulmonary Fibrosis Nervous System Morphinans Physiology Cough Phenols Parkinson’s Disease Opioid Receptors Pruritus Dyskinesia Peripheral Nervous System Prurigo Prurigo Nodularis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.0 |
| 52 Week Low | 0.9712 |
| Average Volume | 521,602 |
| 200-Day Moving Average | 2.90 |
| 50-Day Moving Average | 3.12 |
| 20-Day Moving Average | 2.98 |
| 10-Day Moving Average | 2.89 |
| Average True Range | 0.22 |
| RSI (14) | 41.52 |
| ADX | 11.08 |
| +DI | 19.80 |
| -DI | 20.10 |
| Chandelier Exit (Long, 3 ATRs) | 2.75 |
| Chandelier Exit (Short, 3 ATRs) | 3.32 |
| Upper Bollinger Bands | 3.22 |
| Lower Bollinger Band | 2.74 |
| Percent B (%b) | 0.06 |
| BandWidth | 16.06 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.06 |
| MACD Histogram | -0.0154 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.21 | ||||
| Resistance 3 (R3) | 3.24 | 3.12 | 3.13 | ||
| Resistance 2 (R2) | 3.12 | 3.01 | 3.11 | 3.11 | |
| Resistance 1 (R1) | 2.95 | 2.94 | 2.89 | 2.92 | 3.08 |
| Pivot Point | 2.83 | 2.83 | 2.81 | 2.82 | 2.83 |
| Support 1 (S1) | 2.66 | 2.72 | 2.60 | 2.63 | 2.46 |
| Support 2 (S2) | 2.54 | 2.65 | 2.53 | 2.43 | |
| Support 3 (S3) | 2.37 | 2.54 | 2.41 | ||
| Support 4 (S4) | 2.34 |
